What diseases are Besudil mesylate tablets mainly used to treat?
Belumosudil mesylate tablets (Belumosudil) is a new drug mainly used to treat chronic graft-versus-host disease (GVHD). Chronic graft-versus-host disease is a common complication that commonly occurs in patients undergoing hematopoietic stem cell transplantation. In this case, the transplanted immune cells (i.e., donor cells) attack the tissues of the host (i.e., recipient), causing a series of immune reactions and damage that seriously affect the patient's quality of life and health status.

Besudil, as a kinase inhibitor, mainly acts on the adenylyl acylase-2 (KMT2A) signaling pathway. It reduces the symptoms of GVHD by regulating cell signaling related to the immune response. Besudil may provide an effective treatment option, particularly in patients with inadequate response to glucocorticoids or other systemic treatments. This allows patients who have failed to respond to traditional treatment options to find new hope.
Clinical studies have shown that patients taking besudil achieved significant improvements in symptom relief and quality of life. The drug can not only control symptoms related to GVHD, such as inflammatory reactions in the skin, liver and gastrointestinal tract, but can also help restore the patient's immune function and reduce the risk of infection. Therefore, besudil provides a novel therapy for the management of chronic graft-versus-host disease.
The indications of Besudil are mainly for patients 12 years old and above. In this group, the incidence of chronic GVHD is relatively high. With the advancement of transplantation technology, more and more patients are surviving, but they are also facing the threat of GVHD. Therefore, effective treatment methods are particularly important. In addition, the application of besudil also reflects the medical community’s continuous exploration and innovation in the treatment of chronic GVHD, aiming to improve patients’ survival rate and quality of life.
Reference: https://www.drugs.com/pro/rezurock.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)